文献速递白血病

ado-trastuzumab emtansine治疗HER2突变肺癌患者:II期篮子试验结果

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
PubMed 文献 · J Clin Oncol · 2018-07-10

这项II期篮子试验评估了ado-trastuzumab emtansine在HER2突变晚期肺腺癌患者中的活性。18例患者接受每3周3.6 mg/kg静脉给药,部分缓解率为44%(95%CI 22%至69%),达到主要终点。中位无进展生存期为5个月(95%CI 3至9个月),毒性包括1或2级输注反应、血小板减少和肝转氨酶升高。

要点

  • ado-trastuzumab emtansine在HER2突变肺癌中部分缓解率达44%(95%CI 22%至69%)
  • 中位无进展生存期为5个月(95%CI 3至9个月)
  • HER2免疫组化为0至2+且不预测缓解,缓解者蛋白表达低

核心结论

  • ado-trastuzumab emtansine在HER2突变肺癌患者中是有活性的药物。
  • 这是该肺癌分子亚组中首个阳性试验。
  • 需要进一步使用和研究该药物。

研究设计与样本

  • II期篮子试验,采用Simon两阶段最优设计。
  • 共治疗18例晚期HER2突变肺腺癌患者。
  • 既往系统治疗中位数为2种(范围0至4种)。
  • 给药方案为ado-trastuzumab emtansine 3.6 mg/kg静脉注射每3周一次直至进展。
  • 主要终点为采用RECIST 1.1评估的总体缓解率。

主要发现

  • 部分缓解率为44%(95%CI 22%至69%),达到主要终点。
  • 缓解见于HER2外显子20插入以及激酶域、跨膜域和细胞外域点突变患者。
  • 2例患者观察到并发HER2扩增。
  • HER2免疫组化范围为0至2+,不预测缓解;缓解者经质谱测定HER2蛋白表达低。
  • 中位无进展生存期为5个月(95%CI 3至9个月)。

关键数值与推荐

  • 部分缓解率44%(95%CI 22%至69%),达到主要终点。
  • 中位无进展生存期5个月(95%CI 3至9个月)。
  • HER2免疫组化范围0至2+,不预测缓解。
  • 缓解者经质谱测定HER2蛋白表达低。

临床怎么用

  • ado-trastuzumab emtansine在HER2突变肺癌患者中显示活性。
  • 作者认为需要进一步使用和研究该药物。

局限性

  • 需要进一步使用和研究该药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Human epidermal growth factor receptor 2 ( HER2, ERBB2)-activating mutations occur in 2% of lung cancers. We assessed the activity of ado-trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in a cohort of patients with HER2-mutant lung cancers as part of a phase II basket trial. Patients and Methods Patients received ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression. The primary end point was overall response rate using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. A Simon two-stage optimal design was used. Other end points included progression-free survival and toxicity. HER2 testing was performed on tumor tissue by next generation sequencing, fluorescence in situ hybridization, immunohistochemistry, and protein mass spectrometry. Results We treated 18 patients with advanced HER2-mutant lung adenocarcinomas. The median number of prior systemic therapies was two (range, zero to four prior therapies). The partial response rate was 44% (95% CI, 22% to 69%), meeting the primary end point. Responses were seen in patients with HER2 exon 20 insertions and point mutations in the kinase, transmembrane, and extracellular domains. Concurrent HER2 amplification was observed in two patients. HER2 immunohistochemistry ranged from 0 to 2+ and did not predict response, and responders had low HER2 protein expression measured by mass spectrometry. The median progression-free survival was 5 months (95% CI, 3 to 9 months). Toxicities included grade 1 or 2 infusion reactions, thrombocytopenia, and elevated hepatic transaminases. No patient stopped therapy as a result of toxicity or died on study. Conclusion Ado-trastuzumab emtansine is an active agent in patients with HER2-mutant lung cancers. This is the first positive trial in this molecular subset of lung cancers. Further use and study of this agent are warranted.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Li BT, Shen R, Buonocore D, et al. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. J Clin Oncol. 2018. PMID: 29989854. doi:10.1200/JCO.2018.77.9777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。